CTOs on the Move

Immunicom

www.immunicom.com

 
Immunicom, Inc. is a privately held medical technology company that develops subtractive therapies for cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom`s blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types and other terminal diseases with a safer side-effect profile than conventional treatments. Immunicom`s lead product, the LW-02 column, previously received FDA Breakthrough Device designation in 2018 for stage IV metastatic cancer, and European regulatory clearance (CE Mark certification) in 2021 for use in adults with advanced, refractory, triple negative breast cancer. Immunopheresis is being evaluated in several global oncology trials for multiple ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.immunicom.com
  • 6048 Cornerstone Court West Suite D
    San Diego, CA USA 92121
  • Phone: 657.202.6388

Executives

Name Title Contact Details
Annette Marleau
Chief Technology Officer Profile

Funding

Immunicom raised $11M on 07/02/2019

Similar Companies

AandL Catheter Technologies

A&L Catheter Technologies is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seattle Genetics

Targeting Cancer. Transforming Therapies. Revolutionary science meets transformative cancer therapy Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency. In addition to one marketed product, we are advancing a strong product pipeline designed to address significant unmet medical needs.

AES OPTICS

AES OPTICS is a Senatobia, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biomea Fusion

Biomea Fusion, Inc. was formed in 2017 by a small group of biotech executives. We are dedicated to developing innovative medicines for patients. It is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care.

Lamination Technologies Inc

Lamination Technologies Inc is a Freeport, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.